|Bid||84.52 x 1100|
|Ask||84.53 x 3100|
|Day's Range||84.29 - 84.91|
|52 Week Range||77.76 - 91.79|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.14%|
The US added 223,000 jobs in May while the unemployment rate dropped to 3.8%. Yahoo Finance's Seana Smith, Pras Subramanian and Andy Serwer discuss the report with Shawn Snyder, Head of Investment Strategy at Citigroup Global.
Obamacare costs are expected to rise as healthier people forgo coverage. Yahoo Finance's Seana Smith, Rick Newman and Dion Rabouin discuss.
After Trump's announcement, are health care stocks in the clear? With CNBC's Eamon Javers, CNBC's Melissa Lee, and the Fast Money traders, Tim Seymour, David Seaburg, Brian Kelly and Steve Grasso.
High and growing health-care costs are a problem for everyone — but especially so for state and local governments. Related: Doctor’s offices are a hot investment — what does that mean for profit vs. patient care?FitchU.S. state and local governments spent 30.7% of their budgets on health care and social services in 2015, an increase from 27.6% in 2005.
Johnson & Johnson (JNJ.N) shareholders have endured a painful year amid worries about prospects for its many businesses, but investors capitalizing on the stock's relatively cheap valuation may be set to apply a Band-Aid to the declines. Shares of J&J, the largest U.S. healthcare company by market value, had slumped 11.2 percent this year as of Friday's close, although recent gains may indicate the start of a rebound. The stock's year-to-date decline compares to more than 2 percent gains for both the S&P 500 healthcare sector (.SPXHC) and the blue chip Dow Jones Industrial Average (.DJI), of which J&J is a member.
Investors looking for a sector level summer rental in the financial markets may want to consider healthcare ETFs, such as the Health Care Select Sector SPDR (XLV). XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.
Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.
Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.
June can be a rough month for U.S. stocks. The sixth month of the year is the fourth-worst for both the S&P 500 and the Dow Jones Industrial Average. Not surprisingly, that the theme of broader market ...
A gain of 47.56% in 2018 for shares of Align Technology, Inc. ( ALGN) likely occurred alongside strong institutional support. Align Technology's shares have been performing very well this year even after a very solid 2017 return (+241.84%), which in our opinion supports a bullish undertone for the stock. Taking a look at how the shares have been trading over the past year, Align Technology's share price gains have coincided with volume increases.
Incyte’s (INCY) consolidated revenue rose to $328.3 million in Q1 2018 compared to $384.1 million in Q1 2017. In Q1 2018, the company reported net revenue of -$2.6 million compared to $29.1 million in Q1 2017.
Previously, we discussed billionaire investor David Tepper’s largest holdings and top buys and sells in the first quarter. In this part, we’ll look at Tepper’s top investment sectors based on his Appaloosa Management holdings.
Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.
After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.
Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to "global freeloading" that has allowed foreign countries to pay less on American-manufactured medicines. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, gained 1.5% Friday while the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, rose 2.7% and VanEck Vectors Generic Drugs ETF (GNRX) , which focuses on generic drug producers, added 2.2%.
Healthcare stocks dipped after President Donald Trump started presenting his plan to cut prescription drug costs, then bounced sharply to trade even higher than pre-speech levels. The SPDR Health Care Select Sector ETF was up about 0.5% before Trump's speech began, then slid to be down 0.1% swinging higher to be up 1.1% at a new intraday high. Some changes to policy announced by Trump and Health and Human Services Secretary Alex Azar included drug price negotiation by government programs, an end to the "gag rule" on pharmacists--who cannot disclose if drug products can be bought for cheaper without using a health plan -- and disclosure of drugs' list prices pharmaceutical advertisements.
Stocks representing the U.S. drug supply chain temporarily tumbled Friday as President Donald Trump proposed a broad plan to lower consumer health costs. Last year, it increased federal lobbying spending by 30 percent, and it may maintain such investments to prevent future follow-through.
The “Job Openings and Labor Turnover Survey” (or JOLTS) data for March was reported on May 8 and contains key information about job openings and total separations. The total number of separations include layoffs, retirements, and voluntary quits. As per the latest JOLTS report, the total separations for March came in at 5.3 million at a rate of 3.6% of the total workforce, an increase from the February reading of 5.2 million and 3.5%, respectively.
Johnson & Johnson’s (JNJ) Darzalex injection is a CD-38 surface protein–directed antibody approved for the treatment of multiple myeloma. Today, JNJ announced that the US Food & Drug Administration (or FDA) approved Darzalex in combination with other drugs for the treatment of multiple myeloma, marking the fifth indication for which Darzalex has FDA approval.
Merck (MRK), one of the largest pharmaceutical companies worldwide, is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company reported its 1Q18 results on May 1. During the quarter, Merck surpassed analysts’ EPS (earnings per share) estimate of $1, but missed their revenue estimate of $10.1 billion, reporting EPS of $1.05 on revenue of $10.0 billion.